These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 1766520)

  • 1. Interaction between ciclosporin and ceftriaxone.
    Soto Alvarez J; Sacristán Del Castillo JA; Alsar Ortiz MJ
    Nephron; 1991; 59(4):681-2. PubMed ID: 1766520
    [No Abstract]   [Full Text] [Related]  

  • 2. Interaction of josamycin with cyclosporin A.
    Torregrosa JV; Campistol JM; Franco A; Andreu J
    Nephron; 1993; 65(3):476-7. PubMed ID: 8290006
    [No Abstract]   [Full Text] [Related]  

  • 3. Does interaction between omeprazole and cyclosporin exist?
    Castellote E; Bonet J; Lauzurica R; Pastor C; Cofan F; Caralps A
    Nephron; 1993; 65(3):478. PubMed ID: 8290007
    [No Abstract]   [Full Text] [Related]  

  • 4. No clinically significant interaction between ciclosporin and isradipine.
    Martinez F; Pirson Y; Wallemacq P; van Ypersele de Strihou C
    Nephron; 1991; 59(4):658-9. PubMed ID: 1837336
    [No Abstract]   [Full Text] [Related]  

  • 5. Decreased cyclosporine concentrations with the addition of an H2-receptor antagonist in a patient on ketoconazole.
    Karlix JL; Cheng MA; Brunson ME; Ramos EL; Howard RJ; Peterson JC; Patton PR; Pfaff WW
    Transplantation; 1993 Dec; 56(6):1554-5. PubMed ID: 8279039
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment with ticlopidine is associated with reduction of cyclosporin a blood levels.
    Feriozzi S; Massimetti C; Ancarani E
    Nephron; 2002 Sep; 92(1):249-50. PubMed ID: 12187118
    [No Abstract]   [Full Text] [Related]  

  • 7. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients.
    Mück W; Mai I; Fritsche L; Ochmann K; Rohde G; Unger S; Johne A; Bauer S; Budde K; Roots I; Neumayer HH; Kuhlmann J
    Clin Pharmacol Ther; 1999 Mar; 65(3):251-61. PubMed ID: 10096257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ideal therapeutic range of cyclosporine in whole blood in kidney-transplanted patients.
    Xu F; Chen ZL; Jin WJ; Xie QD; Shi XH
    Int J Clin Pharmacol Res; 1993; 13(4):221-4. PubMed ID: 8150548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of fluconazole with ciclosporin A.
    Torregrosa V; De la Torre M; Campistol JM; Oppenheimer F; Ricart MJ; Vilardell J; Andreu J
    Nephron; 1992; 60(1):125-6. PubMed ID: 1738408
    [No Abstract]   [Full Text] [Related]  

  • 10. Multi-drug resistance gene-1 (MDR-1) haplotypes and the CYP3A5*1 genotype have no influence on ciclosporin dose requirements as assessed by C0 or C2 measurements.
    Fredericks S; Jorga A; MacPhee IA; Reboux S; Shiferaw E; Moreton M; Carter ND; Holt DW; Johnston A
    Clin Transplant; 2007; 21(2):252-7. PubMed ID: 17425754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction between cyclosporine and felodipine in renal transplant recipients.
    Pedersen EB; Sørensen SS; Eiskjaer H; Skovbon H; Thomsen K
    Kidney Int Suppl; 1992 May; 36():S82-6. PubMed ID: 1614074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction between glipizide and cyclosporine: report of two cases.
    Chidester PD; Connito DJ
    Transplant Proc; 1993 Apr; 25(2):2136-7. PubMed ID: 8470294
    [No Abstract]   [Full Text] [Related]  

  • 13. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine.
    Simonson SG; Raza A; Martin PD; Mitchell PD; Jarcho JA; Brown CD; Windass AS; Schneck DW
    Clin Pharmacol Ther; 2004 Aug; 76(2):167-77. PubMed ID: 15289793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of ciclosporin on triglyceridemia in long-term renal transplant recipients.
    Verzola A; Bedani PL; Gilli P
    Nephron; 1999 Feb; 81(2):240-1. PubMed ID: 9933763
    [No Abstract]   [Full Text] [Related]  

  • 15. Cyclosporine levels in diabetic (type 1) patients undergoing kidney and pancreas transplantation: role of a new galenica formulation.
    Storck M; Mickley V; Gräb C; Steinbach G; Abendroth D
    Transplant Proc; 1994 Oct; 26(5):2996-8. PubMed ID: 7940946
    [No Abstract]   [Full Text] [Related]  

  • 16. [Cyclosporine dose monitorization in renal transplantation C2 vs C0].
    Marcén R; Villafruela JJ
    Nefrologia; 2005; 25(2):106-12. PubMed ID: 15912646
    [No Abstract]   [Full Text] [Related]  

  • 17. Cyclosporine-methyltestosterone interaction.
    Goffin E; Pirson Y; Geubel A; van Ypersele de Strihou C
    Nephron; 1991; 59(1):174-5. PubMed ID: 1944742
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of three administration schedules of cyclosporine A in humans.
    Hébert MJ; Madore F; Fugère J; Trahan F; Mongrain S; Daloze P; Corman J; Smesters C; Aboujaoude M; St-Louis G
    Transplant Proc; 1994 Oct; 26(5):2509-10. PubMed ID: 7940769
    [No Abstract]   [Full Text] [Related]  

  • 19. Interaction of lipids and cyclosporine.
    Morgenstern BZ; Murphy M; Milliner DS
    Transplant Proc; 1994 Feb; 26(1):130. PubMed ID: 8108906
    [No Abstract]   [Full Text] [Related]  

  • 20. Interaction between probucol and cyclosporine in renal transplant patients.
    Gallego C; Sánchez P; Planells C; Sánchez S; Monte E; Romá E; Sánchez J; Pallardó LM
    Ann Pharmacother; 1994; 28(7-8):940-3. PubMed ID: 7949516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.